Cortechs.ai Bolsters AI Neuroimaging Prowess with ZepMed Technology Acquisition
Cortechs.ai Strengthens AI Neuroimaging Leadership with ZepMed Acquisition
Cortechs.ai, a recognized leader in the field of artificial intelligence-driven neuroimaging software, has announced a significant strategic move with the acquisition of intellectual property from ZepMed, LLC. This acquisition includes ZepMed's patented CT imaging technologies and its highly regarded flagship product, NeuroAlign CT™. The integration of these advanced technologies is set to bolster Cortechs.ai's standing at the forefront of radiological innovation and substantially expand its array of sophisticated solutions offered to clinicians globally.
Expanding Capabilities and Enhancing User Tools
Kyle Frye, CEO of Cortechs.ai, articulated the strategic importance of this acquisition, stating, "With this acquisition, we're not just expanding our portfolio, we're building on ZepMed's foundation to elevate development and deliver even more powerful tools to our users." He further emphasized that this represents an "exciting growth milestone" as the company continues its mission to enhance the solutions relied upon by healthcare professionals worldwide.
ZepMed's NeuroAlign CT™: A Leap in CT Imaging Analysis
ZepMed has established a strong reputation for its pioneering contributions to CT imaging. The company's NeuroAlign CT™ software has achieved Class II FDA clearance and is distinguished by its ability to automate crucial aspects of head CT scan analysis, including segmentation, alignment, and reformatting. This technological advancement is designed to significantly enhance diagnostic accuracy and optimize radiology workflows. By streamlining these processes, NeuroAlign CT™ empowers clinicians to detect subtle changes in brain anatomy with a heightened degree of confidence and speed, leading to more precise and timely diagnoses.
Synergy and Future Development
Douglas Bates, MD, co-founder of ZepMed, expressed considerable pride in the NeuroAlign® technology developed by his team. He conveyed enthusiasm about the prospect of the technology reaching its "full potential in the hands of Cortechs.ai." Dr. Bates highlighted the anticipated benefits of Cortechs.ai's robust support and development team, predicting that they will be instrumental in enhancing the user experience and introducing new features. This, he noted, will ensure that the technology benefits a broader spectrum of clinicians and patients across the globe.
Architecting a Continuum of Care in Precision Medicine
Daniel Livschutz, Chairman of the Board for Cortechs.ai and Founding Partner of VILAS Ventures, underscored the acquisition's alignment with the company's overarching strategy. "This ownership strengthens our commitment to delivering AI-powered diagnostic solutions that span both neuroimaging and radiology," Livschutz stated. He further elaborated on the vision, explaining, "With the integration of ZepMed's innovations, we're not just adding capabilities, we're architecting a continuum of care that spans surveillance, diagnosis, and risk." This strategic positioning aims to transcend existing industry silos and foster a multimodal ecosystem that more effectively serves the needs of patients, clinicians, and payers alike. Livschutz concluded by expressing excitement about the continued development of the Cortechs.ai platform and its anticipated global impact.
Accelerating Innovation and Improving Patient Outcomes
By bringing ZepMed's advanced CT imaging technology under its ownership, Cortechs.ai is poised to accelerate its innovation pipeline and significantly broaden its neuroimaging portfolio. This strategic integration reinforces Cortechs.ai's leadership in the rapidly evolving field of AI-powered radiology. The company remains steadfast in its mission to improve patient outcomes through the delivery of precision diagnostics, leveraging cutting-edge technology to enhance the accuracy, efficiency, and accessibility of medical imaging analysis.
About Cortechs.ai
Cortechs.ai is dedicated to revolutionizing disease screening and early detection through its advanced medical imaging software. The company specializes in quantifying and tracking neurodegenerative diseases and assisting in the detection of clinically significant cancer. With a suite of FDA-cleared products designed for diagnosing and monitoring neurodegenerative conditions, traumatic brain injuries, and prostate cancer, Cortechs.ai provides radiologists, neurologists, oncologists, and researchers worldwide with effective and cost-efficient tools for assessing brain abnormalities and other conditions.
About ZepMed
ZepMed is recognized as an innovator in medical imaging software, with a particular focus on advanced CT solutions that enhance the speed and accuracy of radiology interpretation. Its flagship product, NeuroAlign CT™, is both FDA-cleared and patented. ZepMed's technology has been instrumental in transforming radiology workflows and bolstering diagnostic confidence in various clinical settings, making it a valuable asset in the pursuit of improved patient care.
AI Summary
Cortechs.ai, a prominent player in AI-driven neuroimaging software, has announced a significant strategic acquisition of intellectual property from ZepMed, LLC. This acquisition encompasses ZepMed's patented CT imaging technologies and its flagship product, NeuroAlign CT™. The move is poised to substantially strengthen Cortechs.ai's leadership position in radiological innovation and broaden its portfolio of advanced solutions available to healthcare professionals worldwide. Kyle Frye, CEO of Cortechs.ai, highlighted that the acquisition is not merely about portfolio expansion but about leveraging ZepMed's established foundation to drive further development and deliver enhanced tools to users, marking an exciting growth milestone. ZepMed, recognized for its pioneering work in CT imaging, developed NeuroAlign CT™, a Class II FDA-cleared software. This innovative technology automates critical processes such as segmentation, alignment, and reformatting of head CT scans. Its primary benefits include improved diagnostic accuracy and streamlined radiology workflows, enabling clinicians to identify subtle changes in brain anatomy with greater speed and confidence. Douglas Bates, MD, co-founder of ZepMed, expressed pride in the NeuroAlign® technology and optimism about its future under Cortechs.ai's stewardship, anticipating enhanced user experience and feature development. Daniel Livschutz, Chairman of the Board for Cortechs.ai and Founding Partner of VILAS Ventures, underscored the acquisition's alignment with Cortechs.ai's commitment to AI-powered diagnostic solutions across neuroimaging and radiology. He emphasized that this integration is instrumental in architecting a comprehensive continuum of care, spanning surveillance, diagnosis, and risk management, thereby moving towards a multimodal ecosystem that benefits patients, clinicians, and payers. The acquisition is expected to accelerate innovation, expand Cortechs.ai's neuroimaging offerings, and reinforce its mission to improve patient outcomes through precision diagnostics.